All In Biotech

Drug Trial Radar · NCT07335588

A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus

A Phase 3, Double-Blinded, Vehicle-Controlled Trial to Investigate the Efficacy and Safety of Twice Daily Delgocitinib Cream in Adult Participants With Lichen Sclerosus During a 12-Week Initial Treatment Period Followed by a 40-Week Continuation Treatment Period

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 552 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

552

Planned (sponsor's estimate)

Start

May 1, 2026

Primary completion

Mar 10, 2028

Study completion Dec 29, 2028

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Jan 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream compared with cream vehicle in the treatment of adult participants with mild to severe lichen sclerosus (LS). The researchers are focusing on female participants because LS is more likely to affect females compared to males. The trial is conducted in 2 parts. Part 1 of the trial enrolls female participants with LS and results in the selection of the optimal dose for Part 2. The selected dose will then be evaluated in Part 2, which will enroll both female and male participants. Assessment of efficacy and safety of delgocitinib cream in male participants with LS will be evaluated in a substudy. For each participant, the trial will last at least 55 weeks and up to 60 weeks.

Conditions

  • Lichen Sclerosus

Interventions

  • DelgocitinibDrug

    Participants will receive delgocitinib BID via topical application.

  • Cream VehicleDrug

    Participants will receive cream vehicle BID via topical administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Achieving Investigator's Global Assessment of Lichen Sclerosus (IGA-LS) Treatment Success (TS) at Week 12Time frame: Week 12

Locations

35 sites in 3 countries. Site status is shown where the registry gives one.

  • LEO Pharma Investigational Site

    Birmingham, Alabama · Recruiting

  • LEO Pharma Investigational Site

    Phoenix, Arizona · Recruiting

  • LEO Pharma Investigational Site

    Scottsdale, Arizona · Recruiting

  • LEO Pharma Investigational Site

    Fremont, California · Recruiting

  • LEO Pharma Investigational Site

    Middlebury, Connecticut · Recruiting

  • LEO Pharma Investigational Site

    Washington D.C., District of Columbia · Recruiting

  • LEO Pharma Investigational Site

    Boca Raton, Florida · Recruiting

  • LEO Pharma Investigational Site

    Clearwater, Florida · Recruiting

  • LEO Pharma Investigational Site

    Jacksonville, Florida · Recruiting

  • LEO Pharma Investigational Site

    Miami, Florida · Recruiting

  • LEO Pharma Investigational Site

    Tampa, Florida · Recruiting

  • LEO Pharma Investigational Site

    Chicago, Illinois · Recruiting

  • LEO Pharma Investigational Site

    Northville, Michigan · Recruiting

  • LEO Pharma Investigational Site

    Rochester, Minnesota · Recruiting

  • LEO Pharma Investigational Site

    New York, New York · Recruiting

  • LEO Pharma Investigational Site

    New York, New York · Recruiting

  • LEO Pharma Investigational Site

    Chapel Hill, North Carolina · Recruiting

  • LEO Pharma Investigational Site

    Bexley, Ohio · Recruiting

  • LEO Pharma Investigational Site

    Portland, Oregon · Recruiting

  • LEO Pharma Investigational Site

    Philadelphia, Pennsylvania · Recruiting

  • LEO Pharma Investigational Site

    Dallas, Texas · Recruiting

  • LEO Pharma Investigational Site

    Murray, Utah · Recruiting

  • LEO Pharma Investigational Site

    Winnipeg, Manitoba, Canada · Recruiting

  • LEO Pharma Investigational Site

    Fredericton, New Brunswick, Canada · Recruiting

  • LEO Pharma Investigational Site

    Guelph, Ontario, Canada · Recruiting

  • LEO Pharma Investigational Site

    Newmarket, Ontario, Canada · Recruiting

  • LEO Pharma Investigational Site

    Richmond Hill, Ontario, Canada · Recruiting

  • LEO Pharma Investigational Site

    Toronto, Ontario, Canada · Recruiting

  • LEO Pharma Investigational Site

    Toronto, Ontario, Canada · Recruiting

  • LEO Pharma Investigational Site

    Waterloo, Ontario, Canada · Recruiting

  • LEO Pharma Investigational Site

    Montreal, Quebec, Canada · Recruiting

  • LEO Pharma Investigational Site

    Québec, Quebec, Canada · Recruiting

  • LEO Pharma Investigational Site

    Saskatoon, Saskatchewan, Canada · Recruiting

  • LEO Pharma Investigational Site

    Liverpool, United Kingdom · Recruiting

  • LEO Pharma Investigational Site

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.